Toll-like receptor (TLR) 2 specific and antagonistic monoclonal antibody
TLR2 represents an “earliest possible” target for prevention and therapeutic
intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Magnetic tornado is stirring up the haze at Jupiter’s poles
Unusual magnetically driven vortices may be generating Earth-size concentrations of hydrocarbon haze. While Jupiter’s Great Red Spot has been a constant feature of the planet for centuries, University of California,…
Cause of common cancer immunotherapy side effect s
New insights into how checkpoint inhibitors affect the immune system could improve cancer treatment. A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation…
New tool makes quick health, environmental monitoring possible
University of Wisconsin–Madison biochemists have developed a new, efficient method that may give first responders, environmental monitoring groups, or even you, the ability to quickly detect harmful and health-relevant substances…